维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

7篇 您的检索式：作者名="Frager M"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Subacute osteoporotic compression fracture: misleading magnetic resonance appearance显示文摘	Frager D Elkin C Swerddlow M	1998	Skeletal Radiol1998，17，：	1
	2	Computed tomography in Crohn disease显示文摘	Frager D H Goldman M Beneventano T C	1983	J Comput Assist Tomogr1983，7，5：	1
	3	Abnormal patterns of pulsatile luteinizing hormone secretion in women with hyperprolactinemia and amenorrhea:responses to bromocriptine显示文摘	Sauder SE Frager M Case GD	1984	J Clin Endocrinol Metab1984，59，：	1
	4	MRI assessment of disc degeneration, 10 years after anterial lumbar interbody fusion 显示文摘	Penta M Sandhu A Frager RD	1995	Spine1995，20，：	1
	5	Computed tomography in Crohn's disease显示文摘	Goldman M Beneventano TC	1983	J Comput Assist Tomogr1983，7，4：	1
	6	Role and integration of mechanisms controlling gastric emptying显示文摘	Horowitz M Deut J Frager R	1994	Dig Dis Sci1994，39，：	1
	7	Treatment of recurrent hepatocellular carcinoma following liver resection,ablation or liver transplantation显示文摘Hepatocellular carcinoma(HCC)is the most common primary liver malignancy and causes one third of cancer related deaths world-wide.Approximately one third of patients with HCC are eligible for curative treatments that include hepatic resection,liver transplantation or imaging guided tumor ablation.Recurrence rates after primary therapy depends on tumor biology and pre-treatment tumor burden with early recurrence rates ranging from 30%-80%following surgical resection and ablation.HCC recurs in over ten percent following liver transplantation for HCC.Treatment modalities for tumor recurrence following resection and ablation include repeat liver resection,salvage liver transplantation,locoregional therapies,and systemic chemotherapy/immunotherapy.Locoregional and immune mediated therapies are limited for patients with tumor recurrence following liver transplantation given potential immune related allograft rejection.Given the high HCC recurrence rates after primary tumor treatment,it is imperative for the clinician to review the appropriate treatment strategy for this disease entity.This article will review the current literature regarding HCC recurrence after primary curative therapies and will discuss the relevant future trends in the HCC field.	Shalom Z Frager Weston Cooper Yvonne Saenger Jonathan M Schwartz	2023	World Journal of Meta-Analysis2023，11，2：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费